Korean J Intern Med.
2013 May;28(3):285-291. 10.3904/kjim.2013.28.3.285.
Procalcitonin as a biomarker of infectious diseases
- Affiliations
-
- 1Division of Infectious Diseases, Department of Internal Medicine, Dong-A University Hospital, Busan, Korea. hleeid@dau.ac.kr
- KMID: 1776447
- DOI: http://doi.org/10.3904/kjim.2013.28.3.285
Abstract
- Traditional biomarkers, including C-reactive protein, leukocytes, erythrocyte sedimentation rate, and clinical signs and symptoms, are not sufficiently sensitive or specific enough to guide treatment decisions in infectious febrile diseases. Procalcitonin (PCT) is synthesized by a large number of tissues and organs in response to invasion by pathogenic bacteria, fungi, and some parasites. A growing body of evidence supports the use of PCT as a marker to improve the diagnosis of bacterial infections and to guide antibiotic therapy. Clinically, PCT levels may help guide the need for empirical antibiotic therapy, source control for infections, and duration of antibiotic therapy. The aim of this review is to summarize the current evidence for PCT in different infections and clinical settings, and to discuss the reliability of this marker in order to provide physicians with an overview of the potential for PCT to guide antibiotic therapy.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Infectious diseases and biomarker use
- Measuring Serum Procalcitonin in Patients with Fever in the ICU to Differentiate Infectious Causes from Non-Infectious Causes
- The value of presepsin, procalcitonin, and C-reactive protein in sepsis associated organ failure in the emergency department: a retrospective analysis according to the Sepsis-3 definition
- Procalcitonin as a Predictive Factor for the Clinical Outcome of Patients with Coronavirus Disease 2019
- Usefulness of Plasma Procalcitonin to Predict Severity in Elderly Patients with Community-Acquired Pneumonia
